Addition of nab-paclitaxel to gemcitabine/cisplatin does not improve overall survival of patients with advanced biliary tract cancers
Adding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median overall survival (OS) time for patients with advanced biliary tract cancers, although it may provide a benefit for subsets of patients with locally advanced disease or gallbladder adenocarcinoma.
Source: news-medical.net